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Background: Despite the steadily escalating psychological and economic burden of
depression, there is a lack of evidence for the effectiveness of available interventions
on functioning areas beyond symptomatology. Therefore, the main objective of this
study was to give an insight into the current measurement of treatment effectiveness
in depression and to provide recommendations for its improvement.
Materials and Methods: The study was based on a multi-informant approach,
comparing data from a systematic literature review, an expert survey with
representatives from clinical practice (130), and qualitative interviews with patients (11)
experiencing depression.
Results: Current literature places emphasis on symptomatic outcomes and neglects
other domains of functioning, whereas clinicians and depressed patients highlight
the importance of both. Interpersonal relationships, recreation and daily activities,
communication, social participation, work difficulties were identified as being crucial
for recovery. Personal factors, neglected by the literature, such as self-efficacy were
introduced by experts and patients. Furthermore, clinicians and patients identified
a number of differences regarding the areas improved by psychotherapeutic or
pharmacological interventions that were not addressed by the pertinent literature.
Conclusion: Creation of a new cross-nationally applicable measure of psychosocial
functioning, broader remission criteria, report of domain-specific information, and a
personalized approach in treatment decision-making are the first crucial steps needed
for the improvement of the measurement of treatment effectiveness in depression.
A better measurement will facilitate the clinical decision making and answer the
escalating burden of depression.
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INTRODUCTION
Clinical guidelines recommend antidepressant medication
[selective serotonin reuptake inhibitors (SSRIs), serotonin–
norepinephrine reuptake inhibitors (SNRIs) and tricyclic
antidepressants (TCAs)] or psychotherapy (e.g., cognitive
behavior therapy, interpersonal psychotherapy) as first choice
treatment options for depression (McAllister-Williams, 2006;
Patten et al., 2009). Results from randomized controlled trials
and clinical guidelines suggest that internet based treatments and
some complementary or alternative therapies, such as exercise or
sleep deprivation, are also effective in the short term (Caliyurt
and Guducu, 2005; Kvam et al., 2016). There is a large body of
research on the effectiveness of these interventions in reducing
depressive symptoms. Symptom improvement remains the main
focus of clinical trials for depression, and the regulatory approval
process for new medications and other interventions is based on
symptomatology (Lam et al., 2015).
In spite of the large number of available interventions for
depression and the huge evidence base on their effectiveness in
terms of reducing symptom severity, the data show that more
than 30% of all cases of depression are not adequately solved by
first agent treatments (Kohn et al., 2004; National Collaborating
Centre for Mental Health, 2010). The meta-analytical evidence of
treatment effectiveness is also modest (Cuijpers et al., 2010; Khan
and Brown, 2015). Moreover, depression has been ranked as one
of the leading causes of burden in the Global Burden of Disease
studies since 1990 (Whiteford et al., 2013). Some predictions
indicate that it will be the greatest cause of disability worldwide
by 2030 (World Health Organization, 2003). According to the
World Health Organization (WHO), approximately 1 million
people die from suicide every year (World Health Organization,
2003), and the majority of cases occur in the context of depression
(Mann et al., 2005). In addition to the psychological burden
on individuals, depression also has significant socio-economic
costs. The direct and indirect costs of depression in the EU
were estimated to be 92 billion in 2010 (Olesen et al., 2012).
Nearly half of the costs were the result of productivity losses,
indicating the enormous negative impact depression has on the
economy.
Even though the lack of early detection and treatment
of depression has been considered the main reason for the
continuous burden of depression (World Health Organization,
2008), the lack of robust results poses the question of
whether the current way of measuring depression is adequate
or should be improved. Between 80 and 95% of all areas
covered by the outcome measures in interventional studies
represent clinical symptomatology (Brockow et al., 2004;
McKnight and Kashdan, 2009; Kamenov et al., 2015). Other
relevant areas of functioning beyond symptoms, such as
activity limitations or participation restrictions in different
domains of life, like social functioning and daily activities
(World Health Organization, 2001), are mostly secondary
outcomes and often do not account for systematic analyses
(Williams et al., 2000). A number of studies state that these
areas might more accurately predict the clinical course of
depression (Stefos et al., 1996), whereas qualitative research
shows that patients have prioritized these functioning outcomes
over symptomatic outcomes and determined the return to
a normal level of functioning at work, home or school
as a major factor for remission in depression (Zimmerman
et al., 2006a). Concurrently, some studies provide evidence
that these outcomes do not correspond to symptom-based
outcomes (Lam et al., 2015). It has been suggested that if
symptoms provide early signs of treatment response, functioning
outcomes beyond symptoms rather provide an indicator of
meaningful change for the patient (McKnight and Kashdan,
2009).
Recently, the Canadian Network for Mood and Anxiety
Treatments (CANMAT) highlighted the need for conceptuali-
zation and measurement of functioning outcomes in clinical
trials (Lam et al., 2015). The lack of gold standard measures
for assessing functioning has also been a major critique in
recent studies (Lam et al., 2015; Madden et al., 2015). To
fill this research gap, the WHO developed an evidence-based
Core Set for depression (Cieza et al., 2004) to address the
broad spectrum of functioning in depression. However, this
tool has not been sufficiently implemented in research studies
due to its complexity and large number of categories (Alvarezz,
2012). In addition, two instruments incorporating symptomatic
outcomes, functioning, and quality of life (QoL) were created—
the Individual Burden of Illness Index for depression (Cohen
et al., 2013) and the Remission from Depression Questionnaire
(Zimmerman et al., 2013)—but their validity is still insufficiently
researched and therefore prevents broader usage in international
research.
Thus, one of the potential reasons for the persisting
burden of depression might be the lack of evidence on
relevant and meaningful functioning difficulties for this disorder,
possibly due to the lack of adequate functioning instruments
(as mentioned above) or to the insufficient implementation
of measures of functioning in clinical trials in general
(Kamenov et al., 2015; Lam et al., 2015; Madden et al.,
2015), which can assess comprehensively all areas affected by
depression. This research gap was the impetus for the current
study, which aimed to provide research recommendations
for improving the measurement of treatment effectiveness in
depression. More specifically, the study aimed to (1) provide
information on the current areas included in the measurement of
treatment effectiveness; (2) identify the areas that representatives
from clinical practice and patients with depression consider
relevant for inclusion in the assessment of psychotherapeutic,
pharmacological or other complementary interventions; (3)
compare the current status quo in research with the clinician
and patient perspectives in order to identify the gaps in
the measurement of treatment effectiveness; and (4) provide
recommendations for its improvement and integration in future
research.
To our knowledge, no previous study has focused on
the improvement of treatment effectiveness measurement in
depression. Such information would be very important for
acquiring policy-relevant information on treatment effectiveness,
disability, and rehabilitation, as well as for linking the available
evidence to the best possible care of depressed patients.
Frontiers in Psychology | www.frontiersin.org 2 March 2017 | Volume 8 | Article 356
fpsyg-08-00356 March 7, 2017 Time: 14:25 # 3
Kamenov et al. Treatment Effectiveness Measurement in Depression
MATERIALS AND METHODS
The present study was based on a comprehensive multi-
informant approach, including data from a systematic literature
review, expert clinicians in the field of depression, and patients
currently diagnosed with depression. The opinion of clinical
experts is essential for overcoming the gap between clinical
research and the care of individual patients (Tonelli, 1999).
However, qualitative research on patients living with a mental
disorder was identified as one of the research priorities for public
mental health in Europe (Forsman et al., 2015).
Systematic Literature Review
Full details of the systematic literature review are provided
elsewhere (Kamenov et al., 2015); a concise description is
presented below. An electronic search for studies assessing
interventions in depressive disorders was performed using
four databases: PsycINFO, PubMed, Web of Science, and
the Cochrane Central Register of Controlled Trials. Studies
published between 2005 and 2015 were identified by including
a set of sensitive MeSH terms and keywords indicative for
intervention, depression and functioning. Studies were included
if (1) participants were older than 18, (2) the diagnosis of
depression was established by a standardized diagnostic tool, and
(3) the sample included at least ten participants.
We grouped the treatments into three main categories:
psychotherapy, pharmacotherapy, and “other” therapies, such as
sleep deprivation and exercise therapy (Patten et al., 2009). All
primary and secondary outcome measures assessing functioning,
QoL or severity of symptoms that were already validated in
depression samples were selected, and all individual items of
the selected tools were extracted. The extracted items were
analyzed and were linked to the International Classification of
Functioning, Disability and Health (ICF) for operationalization
purposes by applying the established linking rules (Cieza
et al., 2005). The linking process was performed by two
researchers. The items were grouped into 10 overarching
categories based on the ICF classification. A frequency analysis
was conducted after all functioning problems were identified
to present the percentage of the areas stratified by type of
intervention.
Expert Survey
The survey was available between March 2015 and March 2016. It
was designed to collect data from practicing clinicians in the field
of depression, assessing interventions used in their daily practice
and the psychosocial difficulties addressed by these treatments.
The short survey consisted of two questions: (1) “Choose the type
of intervention(s) you usually use in your daily practice”; and (2)
“List the psychosocial difficulties that this intervention(s) aims
to improve in individuals with depression.” Participants could
choose up to ten interventions. The aim was to obtain experts’
opinion on the areas that are captured by the specific treatments
and that should be included in the assessment of interventions
for depression. All answers concerning psychosocial difficulties
were linked to the ICF categories according to the existing rules
(Cieza et al., 2005). Additionally, some demographic data were
collected.
To reflect different opinions and achieve a maximum
variation sampling, a wide range of clinicians were approached:
psychiatrists, psychotherapists, primary health care doctors and
other physicians, social workers, and nurses, amongst others.
Clinicians were selected if they had at least 2 years of clinical
expertise in depression. In addition, we searched for the highest
possible variability in terms of age, gender, nationality, and type
of therapy used in daily practice by the clinicians. Potential
participants were identified through a number of sources—
internal databases of international experts working in depression,
heads of psychiatric hospitals and departments, professional
websites for clinicians working in depression1 —and through a
snowball approach. Experts were sent an email invitation for
participation in the survey. We expected a 50–70% non-response
rate (Archer, 2008; Horgan and Dimitriou, 2015). Our target was
to obtain a sample of 100 experts, and therefore the survey was
sent to nearly 250 experts in depression. The study aimed to
approach European experts; therefore, the majority of clinicians
resided in Europe. However, for comparison purposes, data from
non-European experts were also collected.
Qualitative Interviews with Patients with
Depression
The aim of the present study was to collect data from
individuals diagnosed with depression on the treatments they
were receiving/had received for depression and the psychosocial
difficulties addressed by the interventions. Therefore, qualitative
individual interviews with outpatients diagnosed with depression
were performed. Participants had to meet the following inclusion
criteria: (1) current, or history of, depressive episode in the
previous 12 months as main diagnosis (depressive episode
[F32], recurrent depressive episode [F33], or currently in
partial or total remission [F33.4] according to the International
Classification of Diseases) (World Health Organization, 1992);
(2) sufficient cognitive capacity to participate in an interview
(score >26 on the mini-mental status examination (MMSE)
(Folstein et al., 1975); (3) knowledge of the local language
(Spanish); (4) age ≥18 years; (5) currently receiving treatment
for depression, namely psychotherapy, pharmacotherapy or other
treatment prescribed by their mental health professional; and (6)
written informed consent. Ethics approval was obtained by the
Hospital La Princesa Ethics Committee for Clinical Research in
Madrid.
The recruitment of participants and data collection was
performed in a public outpatient mental health unit at Hospital
La Princesa (Madrid, Spain). Two mental health professionals
working in the unit (one psychologist and one psychiatrist)
collected the data between September 2015 and March 2016.
All patients who met the inclusion criteria were informed
about the study and invited to participate. All participants who
agreed to participate gave their consent. The study consisted
of a face-to-face interview with a research team member and
comprised two parts. The first part was a series of demographic
1http://www.commonlanguagepsychotherapy.org
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and clinical questions, which aimed to collect information on
the patients’ background (e.g., gender, age, clinical information,
such as diagnosis and severity of depression, number of
previous episodes, onset of the disorder and occupation). The
second part assessed the type of treatment (psychotherapeutic,
pharmacological, or other) patients had received or were
receiving, and their experience with the respective treatment.
During an open personal interview, participants were asked
about the psychosocial difficulties they were experiencing or
had experienced in the past, and the ones that had or had
not improved with the specific treatment they received. Data
collection continued until a saturation point was reached.
Saturation of data is a commonly used approach in qualitative
research, indicating that there is a point in the analysis of data
when sampling more data will not lead to more information
related to the research questions (Glaser and Strauss, 1967).
In this moment, researchers are allowed to stop sampling data
and to round off the analysis. In the current study, the data
collection continued until three consecutive patients in the same
group of treatment (pharmacological or psychological) did not
report new information, neither on the interventions received,
nor on the psychosocial difficulties identified. When we reached
the saturation point for both psychological and pharmacological
interventions, we stopped with the recruitment of patients.
Participants receiving psychotherapy were allowed to receive
additional antidepressant pharmacotherapy when they met the
following criteria: no antidepressant dosage change 1 month
prior to the start of the psychotherapeutic sessions or during
the psychotherapeutic treatment. As only two patients had been
treated with other (alternative or complementary) therapies,
no data on “other” therapies is available from this qualitative
study.
Recordings of the individual interview sessions were
transcribed verbatim. The transcripts were checked by the
moderator and the information was extracted and double-
checked. All content concerning psychosocial difficulties was
translated into English and coded according to ICF categories
following the existing ICF linking rules (Cieza et al., 2005).
Codification of themes and subthemes for interventions and
psychosocial difficulties was double-checked by an independent
researcher and analyzed by NVIVO program, version 11. All
frequencies were analyzed with SPSS, version 21.
RESULTS
Study Characteristics
Literature Review
A total of 247 articles, including 71,904 participants, were
included in the final synthesis. A total of 66 interventions
were identified, all of them grouped into three main categories:
psychotherapies (N = 22), pharmacotherapies (N = 20) or
other therapies (N = 24). The most common intervention
within the psychotherapeutic category was CBT. Fluoxetine
in particular and the group of SSRIs in general were the
most prevalent antidepressants. Among the remaining therapies,
St. John’s wort was the first agent. A full summary of the
study characteristics can be found elsewhere (Kamenov et al.,
2015).
Expert Survey
The study was sent to 250 practicing clinicians, with a 52%
response rate. 130 clinicians from around the world filled out the
survey. 95 were professionals from 21 countries in Europe, and 35
(27%) were residing outside Europe. Among the non-Europeans,
there were representatives from all continents, primarily from
North and South America, with 15. The average age of the
participants was 43 years (SD = 10.5, range: 23–65). Males were
a slight majority (55%). Experts’ characteristics can be seen in
Table 1.
Qualitative Interviews with Patients
We conducted individual interviews with 11 patients who were
receiving/had received in the last 12 months pharmacological or
psychological treatment. Patients’ diagnoses varied from being in
partial remission (N = 4) to experiencing a current mild (N = 2)
or moderate episode (N = 5) of a major depressive disorder. The
average age of the participants was 58 years (SD = 12), women
were majority (N = 8). Patients’ characteristics can be seen in
Table 2.
Comparison between Literature,
Clinician, and Patient Perspectives on
Treatment Effectiveness
Results from the literature review showed that items related to
clinical symptoms—such as global mental functions (confidence,
temperament, personality functions), specific mental functions
(emotional functions, cognitive functions, body image), energy
(energy level, appetite) and sleep functions—accounted for about
65% of the total number of areas addressed within the outcome
measures. Body functions representing somatic symptoms (e.g.,
pain, digestive or sexual problems) accounted for an additional
15–18% across studies. Other areas of functioning beyond
symptomatology; such as interpersonal relationships, leisure
activities, daily tasks and demands; or major life areas, such as
employment or education, represented a very small percentage:
15–20% varying across the categories of interventions. Domains
TABLE 1 | Characteristics of the experts (N = 130) participating in the
online survey.
Variable N (%)
Age
18–34 32 (24.6%)
35–49 65 (50%)
50–64 31 (23.8%)
65+ 2 (1.5%)
Females 59 (45%)
Years of experience mean (SD) 14 (10.23)
Non-European experts 35 (27%)
Psychiatrists 73 (56%)
Psychologists 44 (34%)
Others 13 (10%)
Frontiers in Psychology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 356
fpsyg-08-00356 March 7, 2017 Time: 14:25 # 5
Kamenov et al. Treatment Effectiveness Measurement in Depression
TABLE 2 | Sociodemographic and clinical characteristics of the patients with depression.
Case Age Gender Occupation Diagnosis Number of previous
episodes
Age of
diagnosis
Comorbidity
1 42 Female Retired Mild episode, currently in partial
remission
0 40 Fibromyalgia
2 68 Female Retired Severe episode, currently in partial
remission
1 64 No
3 48 Male Currently working Moderate episode, currently in partial
remission
0 33 No
4 55 Female Unemployed Recurrent depression, currently in
partial remission
10 25 Personality disorder
5 62 Female Housewife Recurrent depression, current
moderate episode
2 55 No
6 86 Female Retired Recurrent depression, current
moderate episode
No info No info No
7 54 Male Currently working Moderate episode 0 52 Psoriasis
8 60 Female Currently working Moderate episode 0 58 Psoriasis
9 65 Female Housewife Mild episode with somatic symptoms 1 53 No
10 48 Male Unemployed Moderate episode 2 38 HIV
11 55 Female Unemployed Mild episode 3 25 Cancer
such as social participation or communication represented a
negligible percentage.
Unlike results from the literature review, expert clinicians
gave minor importance to areas related to clinical symptoms
(65%, varying across therapies – from 54% in psychotherapy
to 67% in pharmacotherapy). To the contrary, the areas
beyond symptomatology had higher importance compared to
their role in the literature (from 30% in pharmacotherapy to
43% in psychotherapies). Interpersonal relationships, general
tasks and demands, employment and education were pointed
out by clinicians as fundamental areas. Communication and
social participation represented a major part (up to 10%)
of the functioning problems covered by therapies. There
were no major differences between the areas identified and
the types of therapy used by European and non-European
experts.
The qualitative interviews with patients showed patterns
similar to those of the expert reports. Patients highlighted the
importance of a set of symptoms that represented 54% of
all functioning areas. The importance of symptoms such as
weight change or change in appetite was underlined by the
participants: “As something that has improved, I can point to
my appetite. I have an appetite again and have gained weight.
I lost five kilos and now I’ve regained them. I think the reason
is that I feel more or less like I did before. . .” (P8). However,
the areas beyond symptomatology (37% of all areas identified)
were also important for patients with depression. Interpersonal
relationships were the only domain that was mentioned by all
patients: “Yes, now I go out and meet people. Before when I saw
someone in a shop I would turn around and leave because I
didn’t want him to stop me and talk to me” (P2). Participants
also highlighted problems at work, communication, and daily
activities as crucial areas. A summary of all relevant areas
found in literature, expert, and patient reports can be seen in
Figure 1.
In addition, expert clinicians and patients identified a list
of personal factors introducing the concept of “self ”—self-
perception, self-efficacy, self-acceptance, self-awareness, self-
help, self-image and self-esteem—as a major part of the
treatment process. These personal factors were neglected in
the studies included in the systematic review, but constituted
a relevant percentage in the answers of clinicians (4%) and
patients (9%).
When the analysis was stratified by type of intervention, the
literature did not reveal any differences among functioning areas
included in studies applying psychotherapy, pharmacotherapy,
or other interventions. However, such differences were found
in the expert reports. Pharmacological treatment appeared to
address symptomatic areas much more than psychotherapy
(67% vs. 53%), whereas psychotherapy focused more on
functioning areas beyond symptoms. Interpersonal relationships
and communication constituted 30% of the total number
of areas covered by psychotherapies, whereas both had a
substantially smaller share in pharmacotherapy (7%) and other
therapies (13%). Furthermore, communication represented 13%
of the total number of areas covered by psychotherapy, but in
pharmacological interventions it constituted only 2%. Likewise,
in patient reports, symptomatic areas (54%) were predominantly
reported by patients under pharmacological treatment. Lack
of motivation for doing things was a salient area on the
list of difficulties, with 80% of all patients reporting it as
an area improved by medication. Regarding psychotherapeutic
interventions, patients identified interpersonal relationships,
communication, and emotional difficulties as the three main
areas of improvement. More specifically, problems within the
family, with an intimate partner or close friends were the most
commonly reported improved difficulties: “Also, I have my family
around now. It affects me in a positive way, because it’s my family
that I’m spending time with; I’m hiking in the mountain with my
mother and my aunts. And this makes me happy” (P4).
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FIGURE 1 | Comparison between the percentages of functioning areas identified in the literature, the expert survey with clinicians, and individual
interviews with patients with depression.
DISCUSSION
This study breaks new ground by identifying the drawbacks
of the current measurement of treatment effectiveness in
depression and by providing research recommendations for its
improvement. This was done by comparing a systematic review
of the literature, examining the areas of functioning included
in the measurement process, and the clinician and patient
perspectives on the actual areas addressed by the treatments.
For comparison of the three sources of data, we adopted as a
framework the ICF. The ICF provides a complete international
standard language and coding system for data comparability. It is
the most comprehensive classification for functioning including
information about body functions and structures, activities and
participation, as well as environmental factors that may have
an impact on functioning. ICF provides a universal common
language that allows us to operationalize the results and identify
the differences between the research and the perspectives of
patients and clinicians.
Our results showed that current research emphasizes
symptomatic outcomes and neglects other domains of
functioning, as opposed to the opinion of clinicians and
depressed patients, who highlighted the importance of both.
The “self ” concept (e.g., self-efficacy, self-awareness), which
was not considered in the literature, was introduced by experts
and patients as a domain that can be improved by treatments
and has a huge impact on the overall condition of individuals.
Furthermore, clinicians and patients identified a number of
differences regarding the areas improved by psychotherapeutic,
pharmacological, and other treatments. Pharmacological
treatments generally improved symptomatic domains to a
higher extent. Experts expressed their preference in choosing
antidepressants when targeting certain symptomatic difficulties,
such as sleep or emotional functioning. Lack of motivation
was an important issue for patients and they acknowledged the
role of medications in its improvement. On the other hand,
psychological treatments were the first choice for patients
and experts when areas beyond symptoms were affected.
Interpersonal relationships, problems in communication or
lack of social participation were areas susceptible to change by
psychotherapies. Self-care activities such as eating, dressing,
taking care of one’s look were also recovered by psychological
interventions. Based on the obtained results, the following
section provides a summary of recommendations for the
improvement of the measurement of treatment effectiveness in
depression.
Identification of the Most Burdensome
Functioning Areas in Depression and
Creation of a New Measure of
Psychosocial Functioning
Our results show that a small percentage of studies apply
instruments measuring functioning areas beyond symptoms.
The few studies that implement such tools do not provide
comprehensive information on functioning, mainly due to the
limited number of areas covered by the instruments (Uebelacker
et al., 2009; Vitriol et al., 2009). All clinicians and patients taking
part in the present study identified a number of functioning
domains (Table 3) as susceptible to change and crucial for
assessment. This list of domains is the first step for the creation
of a new instrument, which should include all relevant areas of
psychosocial functioning, addressing together symptomatology
and areas of functioning beyond symptoms. This unique tool
should be comprehensive enough in regard to the health
condition, and quick to administer if needed, to be applied in
a clinical settings where practitioners have limited time and
resources (Wittchen et al., 2001)— something that would provide
comparability across studies. The instrument should also take
into account differences across groups of patients by weighting
the domains according to their importance. Thus, if for a certain
group of patients who share similar characteristics, difficulties
in communication and daily activities are prominent domains
these should be given more weight than the other domains.
However, our study is the first to assess this broad spectrum
of psychosocial difficulties, and therefore more quantitative
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TABLE 3 | Functioning areas identified for inclusion in the measurement of treatment effectiveness.
Mental functioning Global and specific mental functions. Represents symptoms such as emotional functions, rumination, anxiety,
anhedonia, feelings of hopelessness and guilt, suicidal ideation, or impaired cognitive functioning
Sleep Problems in the onset, maintenance and quality of sleep
Energy level Fatigue, loss of energy and motivation
Somatic functioning Somatic symptoms, pain or impaired sexual functioning
Interpersonal interactions and relationships Relationships within the family, intimate relations, relations with friends, or informal social relationships
Recreational and leisure activities Hobbies, socializing, sports, arts and culture
Communication and social participation Problems in communication, receiving and producing messages, participation in society, social activities, etc.
General tasks and demands Problems in daily activities, household responsibilities, self-care, handling stress
Major life areas Employment, education, economic life
Personal factors Self-esteem, self-efficacy, self-image, self-awareness
and qualitative research is needed to replicate our results and
determine the most relevant domains of functioning.
Another approach that can facilitate functioning data
collection is the application of patient-generated outcome
measures or the integration of patient-generated individual items
in a patient-reported tool. The patient-generated information is
a novel approach to evaluating outcomes that allows patients to
formulate their own responses in an open-ended format based
on each patient’s own stated goals and expectations (Tang et al.,
2014). Even though this approach has certain limitations: e.g., it
requires more extensive resources for developing and training
personnel to score answers in a standardized format, and is
less amenable for deriving comparisons across populations, it
can provide valuable information on the living experience of
depression and therefore should be given the necessary attention.
A Cross-Nationally Applicable Measure
of Functioning
The majority of studies included in the systematic review
provided evidence only from high-income countries. Knowledge
on relevant areas in depression from low- and middle-income
countries is sparse. The results from the expert survey did not
reveal major differences in the answers of European and non-
European clinicians; however, these results are not generalizable
due to the small number of non-European clinicians. This lack
of evidence suggests that a new instrument comprehensively
assessing all relevant functioning areas should be also validated
in different cross-national samples. Moreover, the instrument
should be sensitive to country differences and be validated
in different settings. More research from low-, middle-, and
high-income countries is needed to provide country-specific
functioning information.
Broader Remission Criteria
Remission of depression is currently defined solely in terms
of symptom reduction (Zimmerman et al., 2006b) according
to cut-off scores on symptom severity scales, such as the
Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1967),
Beck Depression Inventory (BDI) (Beck et al., 1961) or the
Montgomery–Åsberg Depression Rating Scale (Montgomery and
Asberg, 1979). A more comprehensive definition of remission
is needed to adequately reflect the experience of depressed
patients under treatment. Our results show that improvement
in functioning areas beyond symptoms is as important as
the reduction in symptomatology. One possibility is the
creation of a new instrument covering not just symptomatic
aspects, but all relevant affected areas. There are already
initial steps in this direction. Cohen et al. (2013) created
an Individual Burden of Illness Index for depression to
measure treatment impact and recovery in depression by
incorporating multidimensional patient-reported outcomes of
symptom severity, functioning, and QoL. Zimmerman et al.
(2014) subsequently validated a new instrument: the Remission
from Depression Questionnaire, encompassing different domains
of functioning and QoL, along with symptomatology. These
authors conclude that their new tool provides a broader
perspective on depressed patients’ condition than purely
symptom-based measures and is more consistent with the
biopsychosocial approach in the treatment of depression.
However, these tools are still in their infancy and need further
validation. Another possibility involves a separate definition
of functional remission alongside symptom assessment. An
example is a study by Mancini et al. (2012), which applied such
criteria, based on the Sheehan Disability Scale (Sheehan, 1983).
Future studies should aim to achieve such broader remission
criteria.
Reporting Domain-Specific Information
Rather than Sum-Scores of
Questionnaires for Functioning
Results from the literature review showed that more than 80% of
the interventional studies published in the last decade reported
only sum-scores of instruments assessing functioning rather
than domain-specific information. Despite some methodological
and practical advantages of aggregating scores from different
domains, these sum-scores also obscure potential differences
among people and do not provide detailed information on
the differential impact of certain functioning domains on the
overall state of depressed persons. A higher sum-score might
mean a higher number of less affected functioning areas
or a smaller number of domains with marked deterioration.
Reporting domain-specific information will potentially reveal
differential trajectories in the course of depression, interrelations
between distinct domains of functioning, and most importantly,
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will lead to a more personalized approach in the treatment of
depression.
Personalized Approach in Treatment
Decision Making
Current treatment decision making is primarily based on
evidence-based medicine. Thus, clinical guidelines recommend
psychotherapy and pharmacological agents for all patients
as first-line treatments. The regulatory approval process for
new medications and other interventions is based primarily
on symptomatology. Our results, however, showed that
psychotherapeutic and pharmacological interventions targeted
the range of functioning difficulties in the population to a
different extent. Moreover, patients and experts highlighted
the importance of functioning difficulties beyond symptoms in
the recovery process. There is a need for a more personalized
approach in treatment decision-making that acknowledges
specific patient needs and accounts for a more comprehensive
array of functioning domains. More research is also needed to
explore the effectiveness of the available interventions in each of
the relevant functioning areas.
Even though the present study considered all possible
perspectives on the measurement of treatment effectiveness,
some methodological limitations should be mentioned. First
of all, the literature review covered only the last 10 years of
research, because we aimed to explore the latest trends in
assessing treatment effectiveness. Secondly, approximately 70%
of the clinicians that took part in the online survey were
European. Even though we achieved a representation of non-
European experts, wider participation of the latter may have
provided different perspectives on the topic. Finally, data was
obtained from only 11 patients from Spain. Our approach was
the attainment of a saturation point in individuals’ answers,
but more patients, with different cultural backgrounds, could
have enriched the data. The qualitative study was the first
to our knowledge to explore such wide array of functioning
difficulties addressed by different interventions. Furthermore,
the use of the ICF classification system as a framework allowed
the comparison between patients’, practitioners’ and literature
perspectives. Therefore, we think that despite the small number
of participants in the qualitative study, our findings are promising
and warrant further investigation.
The present study is the first to our knowledge to provide
recommendations for improved treatment measurement using
a methodology based on a multi-informant approach. Clinician
and patient perspectives are essential for informing the context
of clinical research, and overcoming the gap between clinical
research and the care of individual patients. We believe that
more accurate and comprehensive evidence on the effectiveness
of available interventions for depression is needed to answer the
steadily escalating societal and economic burden of the disease.
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